Key Finding
TCM syndrome diagnoses and specific acupuncture point selection did not predict treatment response in postmenopausal hot flushes, suggesting other factors may be more important for clinical outcomes.
This study examined how acupuncture helps women experiencing hot flushes after menopause. Researchers in Norway followed 267 women, with 134 receiving acupuncture treatment plus self-care advice and 133 receiving only self-care advice. The acupuncture group received 10 treatment sessions from experienced practitioners trained in Traditional Chinese Medicine (TCM).
The practitioners diagnosed each woman according to TCM principles before selecting acupuncture points. Half of the women were diagnosed with "Kidney Yin Xu," a TCM pattern associated with menopausal symptoms. Interestingly, researchers found that the specific TCM diagnosis didn't affect whether women responded well to treatment. Similarly, the exact acupuncture points chosen didn't determine success rates.
Most practitioners used a core set of eight common points (SP6, HT6, KI7, KI6, CV4, LU7, LI4, and LR3) for all patients, regardless of their specific diagnosis, though they also added individualized points for each woman. Both responders and non-responders received similar point selections, suggesting that other factors beyond point selection may contribute to treatment success.
The study reported no serious side effects from acupuncture treatment. The main Acuflash study (reported separately) found that acupuncture plus self-care led to clinically meaningful reductions in hot flushes and improvements in quality of life compared to self-care alone.
What this means for patients: Acupuncture appears to be a safe and effective option for managing menopausal hot flushes, though researchers don't yet fully understand why it works for some women better than others. If you're considering acupuncture for menopausal symptoms, seek a qualified practitioner with appropriate training and experience in Traditional Chinese Medicine.
This secondary analysis of the Acuflash randomized controlled trial (n=267) examined TCM syndrome diagnoses, point selection, and their relationship to treatment outcomes for postmenopausal vasomotor symptoms. The acupuncture group (n=134) received 10 treatments from experienced TCM practitioners who performed individualized diagnoses and point selection.
Fifty percent of participants received a primary diagnosis of Kidney Yin Xu. No statistically significant differences in response rates or health-related quality of life improvements were found between different syndrome diagnosis groups. A core set of eight points (SP6, HT6, KI7, KI6, CV4, LU7, LI4, LR3) was consistently used across all syndromes, supplemented with individualized point selections. Core point selection frequency showed no significant differences between responders and non-responders.
No serious adverse events were reported. The findings suggest that factors beyond TCM syndrome differentiation and specific point selection—possibly including needling technique, practitioner-patient relationship, or non-specific treatment effects—may influence clinical outcomes. This pragmatic trial demonstrates acupuncture's safety profile while raising important questions about mechanisms underlying successful treatment of menopausal symptoms.
Browse our directory of verified licensed practitioners near you.
Find a practitioner →📌 Dysregulation of m7G RNA modifications, catalyzed by three major methyltransferase complexes in the CNS, is associated with the pathogenesis of multiple neurological diseases including Alzheimer's disease, ALS, epilepsy, glioblastoma, and ischemic stroke.
📌 Acupuncture significantly reduced thyroid antibodies (TPOAb and TGAb) and TSH levels in Hashimoto thyroiditis patients, though methodological limitations prevent reliable clinical recommendations pending higher-quality research.
📌 Liproxstatin-1 significantly reduced cerebral ischemia-reperfusion injury in rats by inhibiting ferroptosis through increasing neuroprotective factors GPX4 and FTH1 while decreasing ferroptosis markers NOX1, ACSL4, COX2, and TFR1.